Tyro Capital Management Invests $4.69M in LENZ Therapeutics

The investment firm now owns 0.32% of the biopharmaceutical company.

Published on Mar. 10, 2026

Got story updates? Submit your updates here. ›

Tyro Capital Management LLC has purchased a new stake of 100,672 shares in LENZ Therapeutics, Inc. (NASDAQ:LENZ), a biopharmaceutical company focused on developing therapies to improve vision. The investment, valued at approximately $4.69 million, represents about 1.7% of Tyro Capital's portfolio and 0.32% ownership in LENZ Therapeutics.

Why it matters

The investment by Tyro Capital Management, a prominent hedge fund, signals confidence in LENZ Therapeutics' pipeline and future prospects. As the company advances its lead product candidates LNZ100 and LNZ101 through late-stage clinical trials for presbyopia, this sizable investment could provide a boost in resources and validation of the company's strategy.

The details

According to a recent 13F filing with the SEC, Tyro Capital Management purchased the 100,672 shares of LENZ Therapeutics in the third quarter of 2025. This investment makes LENZ Therapeutics the 10th largest holding in Tyro Capital's portfolio, accounting for 1.7% of the firm's total assets.

  • Tyro Capital Management purchased the LENZ Therapeutics shares in the third quarter of 2025.

The players

Tyro Capital Management LLC

A prominent hedge fund that has invested $4.69 million in LENZ Therapeutics, representing 1.7% of its portfolio and 0.32% ownership in the biopharmaceutical company.

LENZ Therapeutics, Inc.

A biopharmaceutical company focused on developing therapies to improve vision, including its lead product candidates LNZ100 and LNZ101 for the treatment of presbyopia.

Got photos? Submit your photos here. ›

The takeaway

Tyro Capital Management's significant investment in LENZ Therapeutics underscores the hedge fund's confidence in the biopharmaceutical company's potential to succeed with its vision-improving therapies. This influx of capital could provide a valuable boost as LENZ Therapeutics continues to advance its pipeline and navigate the competitive landscape of ophthalmology treatments.